BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA)

Market Closed
15 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
19. 84
+1.8
+9.9778%
$
594.86M Market Cap
- P/E Ratio
- Div Yield
730,916 Volume
- Eps
$ 18.04
Previous Close
Add Transaction
Day Range
18.05 19.92
Year Range
4.07 24
Want to track BIOA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
BIOA ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of BioAge Labs, Inc. Shareholders Who Lost Money

BIOA ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of BioAge Labs, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

Accesswire | 1 year ago
Bronstein, Gewirtz & Grossman, LLC Encourages BioAge Labs, Inc. (BIOA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages BioAge Labs, Inc. (BIOA) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.

Accesswire | 1 year ago
BioAge Labs, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by BioAge Labs, Inc. (BIOA)

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

Accesswire | 1 year ago
Crude Oil Gains 2%; BioAge Labs Shares Plunge

Crude Oil Gains 2%; BioAge Labs Shares Plunge

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday.

Benzinga | 1 year ago
BioAge Labs, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

BioAge Labs, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

BOSTON, MA / ACCESSWIRE / December 9, 2024 / Block & Leviton is investigating BioAge Labs, Inc. (Nasdaq:BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses.

Accesswire | 1 year ago
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.

Benzinga | 1 year ago
BioAge discontinues mid-stage trial of obesity drug

BioAge discontinues mid-stage trial of obesity drug

BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's tirzepatide for the treatment of obesity.

Reuters | 1 year ago
Prediction: These 2 Stocks Could Soar in 2025

Prediction: These 2 Stocks Could Soar in 2025

The key word here is "could."

Fool | 1 year ago
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

Fool | 1 year ago
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now

2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now

One of these businesses is a risky play, but the other is very likely to succeed.

Fool | 1 year ago
An Airline, Biotechs, and More See Huge Insider Buying

An Airline, Biotechs, and More See Huge Insider Buying

24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying.

247wallst | 1 year ago
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

There's a chance that its lead candidate could become one of the top drugs ever.

Fool | 1 year ago
Loading...
Load More